Skip to content

Repligen RGEN Debt-to-equity

Debt-to-equity at other companies

TEC
Bio-TechneTECH
0.1×-0.1×
Revvity logo
RevvityRVTY
0.5×+0.1×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
0.8×+0.1×
Danaher logo
DanaherDHR
0.4×0.0×
Agilent Technologies logo
Agilent TechnologiesA
0.5×-0.1×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.1×-0.1×

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Current ratio9.2×+2.4×

Where this comes from

Calculated from Repligen’s reported figures.

Based on the most recent quarter.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's debt-to-equity?
Repligen (RGEN) reported debt-to-equity of 0.3× in Q1 2026.
How has Repligen's debt-to-equity changed year-over-year?
Repligen's debt-to-equity increased by 320.9% year-over-year, from 0.1× to 0.3×.
What is the long-term trend for Repligen's debt-to-equity?
Over 5 years (2020 to 2025), Repligen's debt-to-equity has grown at a 73.7% compound annual growth rate (CAGR), from 0× to 0.3×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.